Proof of Mechanism Study of GSK2330811 in Diffuse Cutaneous Systemic Sclerosis

NCT03041025 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

35

Enrollment

INDUSTRY

Sponsor class

Conditions

Scleroderma, Systemic

Interventions

DRUG: GSK2330811
DRUG: Placebo

Sponsor

GlaxoSmithKline